AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 401827
Drug: Disodium ethane‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium ethane‐1 hydroxy‐1, 1‐diphosphonate (EHDP) at doses of 10 or 20 mg/kg/day (non-randomized)
Trial: 401827
Drug: Disodium ethane‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium ethane‐1 hydroxy‐1, 1‐diphosphonate (EHDP) at 5 mg/kg/day
Trial: 401827
Drug: Disodium ethane‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium ethane‐1 hydroxy‐1, 1‐diphosphonate (EHDP) (various doses)
Trial: 401827
Drug: Disodium ethane‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium ethane‐1 hydroxy‐1, 1‐diphosphonate (EHDP) (higher doses)
Trial: 23548119
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine use
Trial: 16926256
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor letrozole
Trial: 10942143
Drug: Bilateral injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral injection of botulinum toxin (BOTOX) at a dosage of 2.5-U
Trial: 10942143
Drug: Unilateral injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral injection of botulinum toxin (BOTOX) at a dosage of 15-U
Trial: 10942143
Drug: Bilateral and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral and unilateral injections of botulinum toxin (BOTOX)
Trial: 3536529
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg once daily
Trial: 3536529
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg three times daily
Trial: 3536529
Drug: Postponing the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postponing the third dose until 10 p.m.
Trial: 2901266
Drug: Betaxolol 10
RxNorm normalized name: betaxolol 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol 10 to 40 mg once daily
Trial: 2901266
Drug: Propranolol 40
RxNorm normalized name: propranolol 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 40 to 160 mg twice daily
Trial: 25313847
Drug: Higher number
RxNorm normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher number of prior PNS implants performed (NPPIP)
Trial: 18061828
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of amphotericin B (2.5 g) and itraconazole (6 months)
Trial: 16836557
Drug: Perioperative iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative iron sucrose (2 x 200 mg/48 hr, IV) plus preoperative erythropoietin (EPO; 1 x 40,000 UI, sc) for patients with preoperative Hb < 130 g/L (Group A)
Trial: 16836557
Drug: Postoperative unwashed
RxNorm normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative unwashed shed blood (USB) for patients with preoperative Hb < 130 g/L (Group B)
Trial: 12569270
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen (17 beta‐estradiol, 100 microg/24 h)
Trial: 10863568
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (newsletters with and without telephone interviews)
Trial: 1777372
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 or 100 mg once daily)
Trial: 9114765
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 or 20 mg once daily)
Trial: 30026341
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus arsenic
Trial: 27423645
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose chemotherapy with stem cell rescue (HDSCR)
Trial: 27423645
Drug: Exploration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exploration of new drugs
Trial: 18457472
Drug: Bazedoxifene (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene (10, 20 and 40 mg)
Trial: 12424044
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg morphine in 20 ml normal saline (Group B)
Trial: 12424044
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg morphine in 20 ml normal saline (Group C)
Trial: 12424044
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml normal saline (Group A)
Trial: 2186991
Drug: Pirbuterol administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirbuterol administered via the Autohaler
Trial: 2186991
Drug: Salbutamol administered
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol administered via the Diskhaler
Trial: 6798902
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium cromoglycate
Trial: 31120601
Drug: De-escalated radiation
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De-escalated radiation therapy (<66 Gy)
Trial: 31120601
Drug: Full-dose radiation
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose radiation therapy (≥66 Gy)
Trial: 25409738
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1 g by intravenous injection followed by 3 g intravenous infusion over 24 hours)
Trial: 22772170
Drug: MMRV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMRV vaccine (2-dose regimen at a 1-month interval)
Trial: 20142523
Drug: Latrepirdine, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latrepirdine, 20 mg 3 times daily (n = 46)
Trial: 17477888
Drug: Agomelatine 25
RxNorm normalized name: Agomelatine 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agomelatine 25 mg/d (with dose adjustment to 50 mg/d if insufficient improvement)
Trial: 17222829
Drug: Tibolone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (2.5 mg/d)
Trial: 12137873
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (0.625 mg/d) plus medroxyprogesterone acetate (5 mg/d)
Trial: 29424236
Drug: Psychological intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychological intervention (up to 10 sessions based on cognitive behavioural therapy) plus usual care
Trial: 22114787
Drug: Vitamin D3‐fortified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3‐fortified yogurt drink (FYD; containing 170 mg calcium and 500 IU/250 mL)
Trial: 22114787
Drug: Plain yogurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain yogurt drink (PYD; containing 170 mg calcium and no vitamin D/250 mL)
Trial: 16464371
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (medication and traditional acupuncture treatment)
Trial: 11131819
Drug: Non-evaluated solutions
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-evaluated solutions
Trial: 11918735
Drug: 40 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mmol/L lactate dialysate
Trial: 9068022
Drug: 38 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 38 mmol/L bicarbonate fluid
Trial: 9068022
Drug: 25 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mmol/L bicarbonate and 15 mmol/L lactate dialysate
Trial: 7877434
Drug: Alpha interferon
RxNorm normalized name: Natural alpha interferon
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha interferon treatment
Trial: 7814812
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose alpha interferon (≤ 200 MU/m2)
Trial: 7814812
Drug: Medium/high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium/high dose alpha interferon (≥ 200 MU/m2)
Trial: 2690545
Drug: 12 g
RxNorm normalized name: PEG-12 GLYCERYL LAURATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 g cholestyramine
Trial: 1099036
Drug: 30% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% sodium thiosulfate application, ultraviolet light, and meladinine tablets (amoidin 0.01 g and amidin 0.005 g)
Trial: 26829647
Drug: 30 or
RxNorm normalized name: Oseni 25/30 Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 or 60 mg gevokizumab every 4 weeks intravenously or subcutaneously
Trial: 20713437
Drug: Cognitive stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive stimulation therapy (CST)
Trial: 18589556
Drug: Epoetin zeta
RxNorm normalized name: Epoetin zeta
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Epoetin zeta (10,000 IU, subcutaneous injection)
Trial: 18589556
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (10,000 IU, subcutaneous injection)
Trial: 16583597
Drug: Whitening lamp
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whitening lamp and peroxide gel (20% hydrogen peroxide)
Trial: 16583597
Drug: No light
RxNorm normalized name: OCTINOXATE 67 mg in 1 mL / TITANIUM DIOXIDE 18 mg in 1 mL TOPICAL LOTION [Valentino Very Valentino Light Lasting Perfecting Foundation Broad Spectrum SPF 26 Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No light treatment with peroxide gel (20% hydrogen peroxide)
Trial: 11854731
Drug: Synthetic patches
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic patches
Trial: 7633717
Drug: Inhaled indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled indomethacin (3 mg/m2 body-surface area)
Trial: 7633717
Drug: Inhaled indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled indomethacin
Trial: 2653057
Drug: Carbamazepine, 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine, 800 mg/day
Trial: 2653057
Drug: Oxazepam, 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxazepam, 120 mg/day
Trial: 71396
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated measles vaccine (Schwarz strain)
Trial: 19117865
Drug: Lucinactant 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lucinactant 90 mg/kg
Trial: 19117865
Drug: Lucinactant 175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lucinactant 175 mg/kg
Trial: 16532712
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II receptor blockers (ARB)
Trial: 15017527
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ARB and ACE inhibition
Trial: 9233053
Drug: Sumatriptan (SU)
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sumatriptan (SU) 6 mg s.c.
Trial: 2877129
Drug: Synvinolin (MK-733)
RxNorm normalized name: vitamin MK 7
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synvinolin (MK-733) 2.5 mg/day
Trial: 2877129
Drug: Synvinolin (MK-733)
RxNorm normalized name: vitamin MK 7
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synvinolin (MK-733) 80 mg/day
Trial: 2877129
Drug: Synvinolin (MK-733)
RxNorm normalized name: vitamin MK 7
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synvinolin (MK-733) (doses ranging from 2.5 mg to 80 mg per day)
Trial: 18226766
Drug: Furosemide (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (intravenous diuretics)
Trial: 12589153
Drug: Clodronate (1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate (1600 mg/day in two divided doses)
Trial: 8668962
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of 1 g of IgG in 10 ml saline
Trial: 8668962
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of 10 ml physiological saline
Trial: 1844697
Drug: Two formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two formulations
Trial: 30106172
Drug: Galcanezumab (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galcanezumab (120 mg subcutaneous injection)
Trial: 23176889
Drug: Subcutaneous allergy
RxNorm normalized name: Callergy Clear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous allergy immunotherapy
Trial: 19254374
Drug: Trial design
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial design barriers, lack of access to treatment, individual barriers of recruiting physicians, insufficient training of recruiting physicians
Trial: 17966072
Drug: Aluminum (Amphojel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum (Amphojel plus citrate) administered orally for 3 days followed by a 3-week washout, then matched placebo for 3 days.
Trial: 17966072
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered for 3 days after aluminum treatment.
Trial: 11556665
Drug: Vestibular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vestibular therapy post-therapy.
Trial: 10074720
Drug: Prophylactic intravenous
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic intravenous immunoglobulin (IVIG) therapy, 750-1000 mg/kg for infants <1000 g, 500-750 mg/kg for infants 1001-1500 g, administered every 2 weeks until 1800 g or discharge
Trial: 10074720
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received saline infusion, administered every 2 weeks until 1800 g or discharge
Trial: 7839076
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone pulse therapy (100 mg in 250 ml 5% dextrose infused over 1 h, repeated every month for 6 months)
Trial: 7839076
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone pulse therapy
Trial: 3060542
Drug: 5% acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% acyclovir cream applied five times daily for 5 days
Trial: 27478849
Drug: Topical pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Topical pirfenidone plus conventional treatment
Trial: 23051740
Drug: High-dose angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose angiotensin II receptor blocker (ARB)
Trial: 24599010
Drug: ARB plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB plus calcium channel blocker (CCB)
Trial: 20674497
Drug: Metabolic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metabolic therapy (coenzyme Q(10), magnesium orotate, lipoic acid, omega‐3 fatty acids and selenium)
Trial: 12452233
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of EMLA cream
Trial: 12452233
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of 1% lidocaine
Trial: 12452233
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of 2% lidocaine
Trial: 10592355
Drug: Twice-weekly hemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly hemodialysis
Trial: 10592355
Drug: Thrice-weekly hemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-weekly hemodialysis
Trial: 2430606
Drug: Atracurium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.6 mg kg‐1
Trial: 1962902
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (FR‐860) at 75 U/kg/day in group I (n = 27)
Trial: 1962902
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (FR‐860) at 150 U/kg/day in group II (n = 29)
Trial: 6273027
Drug: 1,25(OH)2D3 (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,25(OH)2D3 (mean dose 0.5 microgram daily)
Trial: 6273027
Drug: D3 (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D3 (dose 100 microgram daily)
Trial: 25599449
Drug: Testosterone replacement
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone replacement (5 g of transdermal gel daily for 14 weeks)
Trial: 24073230
Drug: Self-administered questionnaire
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered questionnaire modes
Trial: 24073230
Drug: Interviewer-administered questionnaire
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interviewer-administered questionnaire mode
Trial: 24073230
Drug: Self-administered modes
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered modes (when completed twice)
Trial: 21416219
Drug: Fenofibric acid
RxNorm normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibric acid 135 mg added to moderate-dose statin (rosuvastatin 20 mg, simvastatin 40 mg, or atorvastatin 40 mg) for 52 weeks
Trial: 21416219
Drug: Fenofibric acid
RxNorm normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibric acid with moderate-dose statin
Trial: 8916520
Drug: Nurse-managed smoking
RxNorm normalized name: PAD,NURSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-managed smoking cessation program including a meeting with the nurse-case manager, videotape, workbook, relaxation audiotape, nicotine replacement therapy, and nurse-initiated phone contacts after discharge
Trial: 23351426
Drug: Adverse information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adverse information on the risks of the combined oral pill
Trial: 23351426
Drug: Promotional material
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promotional material on the vaginal ring and transdermal patch
Trial: 16730732
Drug: THD 1g
RxNorm normalized name: THD-DP-FM
DrugBank: Blarcamesine (DB05592)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THD 1g daily
Trial: 11936564
Drug: Voriconazole 200
RxNorm normalized name: voriconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole 200 mg q 12 h
Trial: 11936564
Drug: Voriconazole 300
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voriconazole 300 mg q 12 h
Trial: 11936564
Drug: Fluconazole 400
RxNorm normalized name: fluconazole 400 MG in 200 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 400 mg OD
Trial: 7703619
Drug: Calcium absorption
RxNorm normalized name: Evening Primrose Oil Oral Capsule, Liquid Filled [CALCIUM ABSORPTION FOR WOMEN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium absorption (net and true) measured in 18-day balances and by a two-isotope deconvolution method (fractional absorption and maximum absorption rate, MAR)
Trial: 1668825
Drug: Systemic adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic adjuvant chemotherapy alone
Trial: 7073151
Drug: Cimetidine, 300
RxNorm normalized name: Cimetidine, 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine, 300 mg four times daily for 1 day
Trial: 31362765
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) - 1-g loading dose followed by 3-g maintenance dose over 24 hours
Trial: 24703047
Drug: Albiglutide 30
RxNorm normalized name: ALBIGLUTIDE 30MG/0.5ML INJ PEN 0.5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albiglutide 30 mg once weekly titrated to 50 mg at week 6
Trial: 24703047
Drug: Liraglutide 0.6
RxNorm normalized name: liraglutide 0.6 mg/0.1 mL (18 mg/3 mL) SUBCUT PEN INJECTOR (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 0.6 mg once daily titrated to 1.2 mg at week 1 and 1.8 mg at week 2
Trial: 22245322
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (placebo group)